{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:12:51Z","timestamp":1789596771110,"version":"build-2803163510"},"reference-count":122,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","jmig.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Minimally Invasive Gynecology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.jmig.2017.10.025","type":"journal-article","created":{"date-parts":[[2017,10,31]],"date-time":"2017-10-31T19:45:58Z","timestamp":1509479158000},"page":"1179-1193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cancer Risk-Reducing Opportunities in Gynecologic Surgery"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3832-2123","authenticated-orcid":false,"given":"Carolyn","family":"Piszczek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire H.","family":"Gould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmig.2017.10.025_bib0010","series-title":"United States Cancer Statistics: 1999\u20132014 Incidence and Mortality Web-based Report","year":"2017"},{"key":"10.1016\/j.jmig.2017.10.025_bib0015","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/01.AOG.0000231680.58221.a7","article-title":"Patterns and progress in ovarian cancer over 14 years","volume":"108","author":"Chan","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0020","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.ygyno.2017.06.032","article-title":"Erratum to \u201cThe histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2)\u201d [Gynecol. Oncol. 144 (2017) 405\u2013413]","volume":"147","author":"Matz","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0025","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1200\/JCO.2016.66.8178","article-title":"Ovarian cancer risk factors by histologic subtype: an analysis from the Ovarian Cancer Cohort Consortium","volume":"34","author":"Wentzensen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0030","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ygyno.2016.11.019","article-title":"Worldwide comparison of ovarian cancer survival: histological group and stage at diagnosis (CONCORD-2)","volume":"144","author":"Matz","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0035","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1001\/jama.2011.766","article-title":"Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial","volume":"305","author":"Buys","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jmig.2017.10.025_bib0040","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/AOG.0b013e31819cda77","article-title":"Results from four rounds of ovarian cancer screening in a randomized trial","volume":"113","author":"Partridge","year":"2009","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0045","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1525-1438.2007.01035.x","article-title":"A randomized study of screening for ovarian cancer: a multicenter study in Japan","volume":"18","author":"Kobayashi","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.jmig.2017.10.025_bib0050","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1006\/gyno.2000.5765","article-title":"Ovarian endometriosis associated with ovarian carcinoma: a clinicopathological and immunohistochemical study","volume":"77","author":"Ogawa","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0055","doi-asserted-by":"crossref","first-page":"481","DOI":"10.4103\/0377-4929.191789","article-title":"Secretory cell outgrowths, p53 signatures, and serous tubal intraepithelial carcinoma in the fallopian tubes of patients with sporadic pelvic serous carcinoma","volume":"59","author":"Mittal","year":"2016","journal-title":"Indian J Pathol Microbiol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0060","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/PGP.0000000000000336","article-title":"The fallopian tube origin and primary site assignment in extrauterine high-grade serous carcinoma: findings of a survey of pathologists and clinicians","volume":"36","author":"McCluggage","year":"2017","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0065","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/01.pas.0000213335.40358.47","article-title":"Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship","volume":"31","author":"Kindelberger","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0070","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/PAS.0b013e3181ef7b16","article-title":"Are all pelvic (nonuterine) serous carcinomas of tubal origin?","volume":"34","author":"Przybycin","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0075","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.jmig.2017.10.025_bib0080","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/path.2091","article-title":"A candidate precursor to serous carcinoma that originates in the distal fallopian tube","volume":"211","author":"Lee","year":"2007","journal-title":"J Pathol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0085","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/PAP.0b013e3181ecdee1","article-title":"A pathologist's road map to benign, precancerous, and malignant intraepithelial proliferations in the fallopian tube","volume":"17","author":"Mehrad","year":"2010","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0090","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jmig.2012.11.010","article-title":"Surgical implications of the potential new tubal pathway for ovarian carcinogenesis","volume":"20","author":"Chene","year":"2013","journal-title":"J Minim Invasive Gynecol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0095","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.humpath.2011.03.003","article-title":"Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer\u2013shifting the paradigm","volume":"42","author":"Kurman","year":"2011","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0100","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1200\/JCO.2008.16.4814","article-title":"Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention","volume":"26","author":"Carlson","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0105","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/PAS.0b013e3181cf3d79","article-title":"The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory","volume":"34","author":"Kurman","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0110","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ajog.2013.04.019","article-title":"The role of the fallopian tube in the origin of ovarian cancer","volume":"209","author":"Erickson","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0115","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/path.1000","article-title":"Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer","volume":"195","author":"Piek","year":"2001","journal-title":"J Pathol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0120","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1097\/01.AOG.0000187892.78392.3f","article-title":"BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?","volume":"106","author":"Cass","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0125","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1200\/JCO.2007.12.2622","article-title":"Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction","volume":"25","author":"Callahan","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0130","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1008433","article-title":"ARID1A mutations in endometriosis-associated ovarian carcinomas","volume":"363","author":"Wiegand","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmig.2017.10.025_bib0135","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.jmig.2017.10.025_bib0140","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jmig.2017.10.025_bib0145","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jmig.2017.10.025_bib0150","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/jnci\/djt095","article-title":"Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE","volume":"105","author":"Mavaddat","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jmig.2017.10.025_bib0155","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/1055-9965.EPI-11-0775","article-title":"Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1\/2 (CIMBA)","volume":"21","author":"Mavaddat","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jmig.2017.10.025_bib0160","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","article-title":"Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation","volume":"32","author":"Finch","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0165","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jmig.2017.10.025_bib0170","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMc1602861","article-title":"Risk-reducing surgery in hereditary breast and ovarian cancer","volume":"374","author":"MacInnis","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmig.2017.10.025_bib0175","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ygyno.2013.12.009","article-title":"Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations","volume":"132","author":"Conner","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0180","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ygyno.2005.06.065","article-title":"Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers","volume":"100","author":"Finch","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0185","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(06)70585-X","article-title":"Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study","volume":"7","author":"Domchek","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0190","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1158\/1055-9965.EPI-12-0149","article-title":"A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers","volume":"21","author":"Sigal","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jmig.2017.10.025_bib0195","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1056\/NEJMoa012158","article-title":"Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations","volume":"346","author":"Rebbeck","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmig.2017.10.025_bib0200","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa020119","article-title":"Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation","volume":"346","author":"Kauff","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmig.2017.10.025_bib0205","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1200\/JCO.2007.13.9626","article-title":"Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study","volume":"26","author":"Kauff","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0210","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S1470-2045(06)70869-5","article-title":"Survival patterns after oophorectomy in premenopausal women: a population-based cohort study","volume":"7","author":"Rocca","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0215","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jama.296.2.185","article-title":"Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation","volume":"296","author":"Finch","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jmig.2017.10.025_bib0220","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/jnci\/djv217","article-title":"RE: breast cancer risk after salpingo-oophorectomy in healthy BRCA1\/2 mutation carriers: revisiting the evidence for risk reduction","volume":"107","author":"Chai","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jmig.2017.10.025_bib0225","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jnci\/djv033","article-title":"Breast cancer risk after salpingo-oophorectomy in healthy BRCA1\/2 mutation carriers: revisiting the evidence for risk reduction","volume":"107","author":"Heemskerk-Gerritsen","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jmig.2017.10.025_bib0230","doi-asserted-by":"crossref","first-page":"7491","DOI":"10.1200\/JCO.2004.00.7138","article-title":"Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study","volume":"23","author":"Eisen","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0235","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1245\/s10434-015-4754-2","article-title":"Multigene panel testing detects equal rates of pathogenic BRCA1\/2 mutations and has a higher diagnostic yield compared to limited BRCA1\/2 analysis alone in patients at risk for hereditary breast cancer","volume":"22","author":"Kapoor","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0240","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrclinonc.2016.90","article-title":"Counselling framework for moderate-penetrance cancer-susceptibility mutations","volume":"13","author":"Tung","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0245","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMra1503523","article-title":"The role of risk-reducing surgery in hereditary breast and ovarian cancer","volume":"374","author":"Hartmann","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmig.2017.10.025_bib0250","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/AOG.0b013e3182864350","article-title":"Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses' health study","volume":"121","author":"Parker","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0255","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/gme.0b013e31818888f7","article-title":"Increased cardiovascular mortality after early bilateral oophorectomy","volume":"16","author":"Rivera","year":"2009","journal-title":"Menopause"},{"key":"10.1016\/j.jmig.2017.10.025_bib0260","doi-asserted-by":"crossref","first-page":"7804","DOI":"10.1200\/JCO.2004.00.8151","article-title":"Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group","volume":"23","author":"Rebbeck","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0265","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/01.AOG.0000228959.30577.13","article-title":"Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations","volume":"108","author":"Schmeler","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0270","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1001\/jama.287.20.2668","article-title":"Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women","volume":"287","author":"Lindsay","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jmig.2017.10.025_bib0275","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/01.AOG.0000431053.33593.2d","article-title":"ACOG Committee Opinion No. 565: hormone therapy and heart disease","volume":"121","author":"\u2022","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0280","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(03)14596-5","article-title":"Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study","volume":"362","author":"Beral","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jmig.2017.10.025_bib0285","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1097\/GME.0000000000000922","article-title":"The North American Menopause Society (NAMS) Continuing Medical Education Activity","volume":"24","author":"\u2022","year":"2017","journal-title":"Menopause"},{"issue":"Suppl 1","key":"10.1016\/j.jmig.2017.10.025_bib0290","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1210\/jc.2009-2509","article-title":"Postmenopausal hormone therapy: an Endocrine Society scientific statement","volume":"95","author":"Santen","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jmig.2017.10.025_bib0295","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jmig.2017.10.025_bib0300","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jmig.2017.10.025_bib0305","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0140-6736(97)08233-0","article-title":"Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer","volume":"350","author":"\u2022","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.jmig.2017.10.025_bib0310","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1001\/archinte.168.8.861","article-title":"Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy","volume":"168","author":"Grodstein","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jmig.2017.10.025_bib0315","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1161\/CIRCULATIONAHA.106.642280","article-title":"Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study","volume":"115","author":"Canonico","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jmig.2017.10.025_bib0320","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/GME.0000000000000921","article-title":"The 2017 hormone therapy position statement of The North American Menopause Society","volume":"24","author":"The NAMS 2017 Hormone Therapy Position Statement Advisory Panel","year":"2017","journal-title":"Menopause"},{"key":"10.1016\/j.jmig.2017.10.025_bib0325","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1002\/cncr.29321","article-title":"Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer","volume":"121","author":"Walker","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.jmig.2017.10.025_bib0330","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/0002-9378(95)90095-0","article-title":"Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses","volume":"172","author":"Raudaskoski","year":"1995","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0335","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1471-0528.2002.01167.x","article-title":"Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response","volume":"109","author":"Raudaskoski","year":"2002","journal-title":"BJOG"},{"key":"10.1016\/j.jmig.2017.10.025_bib0340","first-page":"963","article-title":"Intrauterine release of levonorgestrel\u2013a new way of adding progestogen in hormone replacement therapy","volume":"79","author":"Andersson","year":"1992","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0345","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejogrb.2005.10.029","article-title":"Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)\u2013a systematic enquiry and overview","volume":"125","author":"Varma","year":"2006","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0350","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ajog.2010.05.038","article-title":"Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1\/2 mutation carriers?","volume":"204","author":"Greene","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0355","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1158\/1055-9965.EPI-07-2703","article-title":"A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study","volume":"17","author":"Greene","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jmig.2017.10.025_bib0360","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1200\/JCO.2006.07.4922","article-title":"Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1\/2 mutation carriers","volume":"25","author":"Madalinska","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0365","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1002\/ijc.23340","article-title":"International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers","volume":"122","author":"Metcalfe","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jmig.2017.10.025_bib0370","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/gtmb.2008.0067","article-title":"Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers","volume":"13","author":"Beattie","year":"2009","journal-title":"Genet Test Mol Biomarkers"},{"key":"10.1016\/j.jmig.2017.10.025_bib0375","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ygyno.2013.12.014","article-title":"Risk management options elected by women after testing positive for a BRCA mutation","volume":"132","author":"Garcia","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0380","author":"Society of Gynecologic Oncology"},{"key":"10.1016\/j.jmig.2017.10.025_bib0385","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1186\/s12885-015-1597-y","article-title":"Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1\/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study","volume":"15","author":"Harmsen","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jmig.2017.10.025_bib0390","author":"Hullu"},{"key":"10.1016\/j.jmig.2017.10.025_bib0395","author":"Anderson"},{"key":"10.1016\/j.jmig.2017.10.025_bib0400","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/01.AOG.0000167394.38215.56","article-title":"Ovarian conservation at the time of hysterectomy for benign disease","volume":"106","author":"Parker","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0405","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1097\/AOG.0b013e3181a11c64","article-title":"Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study","volume":"113","author":"Parker","year":"2009","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0410","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1940-6207.CAPR-11-0430","article-title":"Bilateral oophorectomy, body mass index, and mortality in U.S. women aged 40 years and older","volume":"5","author":"McCarthy","year":"2012","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.jmig.2017.10.025_bib0415","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/jnci\/dju410","article-title":"Ovarian cancer risk after salpingectomy: a nationwide population-based study","volume":"107","author":"Falconer","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jmig.2017.10.025_bib0420","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/aogs.12516","article-title":"Tubal ligation and salpingectomy and the risk of epithelial ovarian cancer and borderline ovarian tumors: a nationwide case-control study","volume":"94","author":"Madsen","year":"2015","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.jmig.2017.10.025_bib0425","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ygyno.2014.10.005","article-title":"Effect of tubal sterilization technique on risk of serous epithelial ovarian and primary peritoneal carcinoma","volume":"135","author":"Lessard-Anderson","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0430","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2015.12.003","article-title":"Bilateral salpingectomy can reduce the risk of ovarian cancer in the general population: a meta-analysis","volume":"55","author":"Yoon","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jmig.2017.10.025_bib0435","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jogc.2016.12.005","article-title":"No. 344-opportunistic salpingectomy and other methods of risk reduction for ovarian\/fallopian tube\/peritoneal cancer in the general population","volume":"39","author":"Salvador","year":"2017","journal-title":"J Obstet Gynaecol Can"},{"key":"10.1016\/j.jmig.2017.10.025_bib0440","doi-asserted-by":"crossref","first-page":"270.e1","DOI":"10.1016\/j.ajog.2016.10.035","article-title":"The performance and safety of bilateral salpingectomy for ovarian cancer prevention in the United States","volume":"216","author":"Hanley","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0445","doi-asserted-by":"crossref","first-page":"471e1","DOI":"10.1016\/j.ajog.2014.01.003","article-title":"Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention","volume":"210","author":"McAlpine","year":"2014","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0450","doi-asserted-by":"crossref","first-page":"603.e1","DOI":"10.1016\/j.ajog.2017.06.007","article-title":"Risks and benefits of opportunistic salpingectomy during vaginal hysterectomy: a decision analysis","volume":"217","author":"Cadish","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0455","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3802\/jgo.2015.26.2.83","article-title":"Ovarian cancer risk reduction through opportunistic salpingectomy","volume":"26","author":"Kwon","year":"2015","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0460","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.fertnstert.2013.07.1997","article-title":"Short-term effects of salpingectomy during laparoscopic hysterectomy on ovarian reserve: a pilot randomized controlled trial","volume":"100","author":"Findley","year":"2013","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jmig.2017.10.025_bib0465","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/j.1447-0756.2007.00669.x","article-title":"Total salpingectomy during abdominal hysterectomy: effects on ovarian reserve and ovarian stromal blood flow","volume":"33","author":"Sezik","year":"2007","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1016\/j.jmig.2017.10.025_bib0470","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/j.fertnstert.2011.03.032","article-title":"Effects of salpingectomy on ovarian response in controlled ovarian hyperstimulation for in vitro fertilization: a reappraisal","volume":"95","author":"Almog","year":"2011","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jmig.2017.10.025_bib0475","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejogrb.2013.06.030","article-title":"Opportunistic and interventional salpingectomy in women at risk: a strategy for preventing pelvic serous cancer (PSC)","volume":"170","author":"Kamran","year":"2013","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0480","author":"Committee on Gynecologic Practice"},{"key":"10.1016\/j.jmig.2017.10.025_bib0485","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.annepidem.2010.10.002","article-title":"Contraception methods, beyond oral contraceptives and tubal ligation, and risk of ovarian cancer","volume":"21","author":"Ness","year":"2011","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0490","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/humupd\/dmq030","article-title":"Tubal ligation and the risk of ovarian cancer: review and meta-analysis","volume":"17","author":"Cibula","year":"2011","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.jmig.2017.10.025_bib0495","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/ije\/dyt042","article-title":"Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies","volume":"42","author":"Sieh","year":"2013","journal-title":"Int J Epidemiol"},{"issue":"8","key":"10.1016\/j.jmig.2017.10.025_bib0500","article-title":"Techniques for the interruption of tubal patency for female sterilisation","author":"Lawrie","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jmig.2017.10.025_bib0505","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/jmwh.12085","article-title":"Breastfeeding and the risk of ovarian cancer: a meta-analysis","volume":"59","author":"Feng","year":"2014","journal-title":"J Midwifery Womens Health"},{"key":"10.1016\/j.jmig.2017.10.025_bib0510","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(08)60167-1","article-title":"Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls","volume":"371","author":"Beral","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jmig.2017.10.025_bib0515","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/AOG.0b013e318291c235","article-title":"Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis","volume":"122","author":"Havrilesky","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0520","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1056\/NEJMoa052627","article-title":"Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome","volume":"354","author":"Schmeler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmig.2017.10.025_bib0525","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01.AOG.0000267500.27329.85","article-title":"Gynecologic cancer prevention in Lynch syndrome\/hereditary nonpolyposis colorectal cancer families","volume":"110","author":"Chen","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0530","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/cncr.23554","article-title":"Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome","volume":"113","author":"Kwon","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.jmig.2017.10.025_bib0535","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10689-011-9444-z","article-title":"A cost-effectiveness analysis of prophylactic surgery versus gynecologic surveillance for women from hereditary non-polyposis colorectal cancer (HNPCC) families","volume":"10","author":"Yang","year":"2011","journal-title":"Fam Cancer"},{"key":"10.1016\/j.jmig.2017.10.025_bib0540","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10689-017-9997-6","article-title":"Quality of life following prophylactic gynecological surgery: experiences of female Lynch mutation carriers","volume":"17","author":"Etchegary","year":"2018","journal-title":"Fam Cancer"},{"key":"10.1016\/j.jmig.2017.10.025_bib0545","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1897-4287-8-6","article-title":"Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients","volume":"8","author":"Riegert-Johnson","year":"2010","journal-title":"Hered Cancer Clin Pract"},{"key":"10.1016\/j.jmig.2017.10.025_bib0550","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ecl.2017.01.013","article-title":"Clinical implications for germline PTEN spectrum disorders","volume":"46","author":"Ngeow","year":"2017","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.jmig.2017.10.025_bib0555","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2017.07.004","article-title":"Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers","volume":"84","author":"Lee","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jmig.2017.10.025_bib0560","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ygyno.2013.03.027","article-title":"The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study","volume":"130","author":"Segev","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0565","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1001\/jamaoncol.2016.1820","article-title":"Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations","volume":"2","author":"Shu","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0570","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/jnci\/94.18.1358","article-title":"Cancer incidence in BRCA1 mutation carriers","volume":"94","author":"Thompson","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jmig.2017.10.025_bib0575","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/modpathol.2012.169","article-title":"Endometrium is not the primary site of origin of pelvic high-grade serous carcinoema in BRCA1 or BRCA2 mutation carriers","volume":"26","author":"Reitsma","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0580","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ygyno.2008.08.035","article-title":"Relationship between tamoxifen use and high risk endometrial cancer histologic types","volume":"112","author":"Bland","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0585","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ygyno.2005.10.026","article-title":"Comparison of uterine malignancies that develop during and following tamoxifen therapy","volume":"101","author":"Ferguson","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0590","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ygyno.2013.02.023","article-title":"Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial","volume":"129","author":"Brinton","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0595","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0140-6736(05)71562-2","article-title":"Tamoxifen and risk of endometrial cancer","volume":"357","author":"Narod","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jmig.2017.10.025_bib0600","first-page":"329","article-title":"Breast cancer linkage consortium. Variation in BRCA1 cancer risks by mutation position","volume":"11","author":"Thompson","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jmig.2017.10.025_bib0605","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/cncr.27720","article-title":"BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma","volume":"119","author":"Pennington","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.jmig.2017.10.025_bib0610","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.ejso.2006.03.032","article-title":"High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma","volume":"32","author":"Biron-Shental","year":"2006","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.jmig.2017.10.025_bib0615","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jamaoncol.2016.1773","article-title":"Drawing the line in risk-reducing gynecologic surgery in women with a BRCA mutation","volume":"2","author":"Leath","year":"2016","journal-title":"JAMA Oncol"}],"container-title":["Journal of Minimally Invasive Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155346501731261X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155346501731261X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T05:42:02Z","timestamp":1719553322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155346501731261X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":122,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S155346501731261X"],"URL":"https:\/\/doi.org\/10.1016\/j.jmig.2017.10.025","relation":{},"ISSN":["1553-4650"],"issn-type":[{"value":"1553-4650","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer Risk-Reducing Opportunities in Gynecologic Surgery","name":"articletitle","label":"Article Title"},{"value":"Journal of Minimally Invasive Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmig.2017.10.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 AAGL. All rights reserved.","name":"copyright","label":"Copyright"}]}}